Meeting Vietnam's Rising Demand

Vietnam's healthcare market will reach $23 billion by 2028, driven by an aging population, rising incomes, and expanding health insurance coverage. Hospital infrastructure, medical devices, and pharmaceuticals present the most attractive entry points. Recent regulatory reforms now permit 100% foreign ownership in certain healthcare segments.

Market Fundamentals

Vietnam's healthcare sector has experienced consistent growth of 10-12% annually over the past five years. Several structural factors support continued expansion:

Demographic shift. Vietnam's population is aging faster than most Southeast Asian peers. The proportion of citizens over 60 will double between 2020 and 2035, creating sustained demand for chronic disease management, geriatric care, and long-term facilities. This demographic transition is irreversible and creates investment opportunities with multi-decade visibility.

Income growth. Per capita GDP has crossed $4,500 and continues to rise. Healthcare spending as a percentage of household expenditure has increased from 4.5% to 6.2% over the past decade. Crucially, the spending is shifting from basic treatment to preventive care, specialist services, and higher-quality facilities.

Insurance expansion. Health insurance coverage now exceeds 90% of the population, up from 60% a decade ago. While reimbursement rates remain low relative to private facility costs, the insurance framework creates a payment infrastructure that reduces patient out-of-pocket burden and makes healthcare businesses more financeable.

Hospital Infrastructure: The Capacity Gap

Vietnam has approximately 25 hospital beds per 1,000 people, below the WHO recommendation of 30 and well below developed Asian economies at 60-80. The gap is particularly acute in specialist care: oncology, cardiology, orthopaedics, and neurology all face capacity constraints that result in wait times, medical tourism outflows, and suboptimal outcomes.

Private hospital investment has accelerated in response. Domestic groups like Vinmec and Hoan My have expanded aggressively, and foreign operators from Thailand, Singapore, and Japan have entered through joint ventures or management contracts. The market is large enough to accommodate multiple players, but location selection and specialty focus are critical determinants of success.

For investors, the most attractive segments are mid-tier general hospitals in provincial cities (where public capacity is most constrained) and specialist facilities in Hanoi and Ho Chi Minh City (where affluent patients seek alternatives to overcrowded public hospitals).

Medical Devices: Import Dependence Creates Opportunity

Vietnam imports over 90% of its medical devices. Diagnostic imaging equipment, surgical instruments, and patient monitoring systems are dominated by Japanese, German, and American manufacturers. The government's stated objective is to increase local production to 30% of domestic consumption by 2030.

This creates two distinct investment opportunities. First, local manufacturing of lower-complexity devices — disposables, consumables, basic instruments — where Vietnamese producers can achieve cost competitiveness. Second, distribution and service partnerships for high-value imported equipment, where the value proposition is not manufacturing but local technical support, maintenance, and regulatory compliance.

Medical device registration through the Ministry of Health is a significant barrier to entry for imported products. The process typically takes 12-18 months and requires extensive documentation. Local partners with established regulatory relationships can accelerate market access considerably.

Pharmaceuticals: A Complex Landscape

Vietnam's pharmaceutical market is approximately $7 billion annually, with generics accounting for roughly 60% of volume but only 30% of value. The market is highly fragmented, with over 200 domestic manufacturers producing primarily for the domestic market and export to neighbouring countries.

Regulatory reform is the most significant recent development. The revised Law on Pharmacy permits 100% foreign ownership in pharmaceutical manufacturing and trading enterprises, removing a longstanding requirement for Vietnamese partnership. This change has triggered renewed interest from Indian, Korean, and European pharmaceutical companies seeking manufacturing bases for Southeast Asian distribution.

However, the regulatory environment remains complex. Drug registration, pricing approval, and bidding procedures for public hospital procurement all involve multiple government agencies and timelines that can extend to several years. Investors without experienced local regulatory counsel often encounter delays that undermine commercial assumptions.

Regulatory Considerations

Healthcare is one of Vietnam's most heavily regulated sectors. Key compliance areas include:

  • Licensing of healthcare facilities through provincial Departments of Health
  • Professional certification requirements for foreign medical practitioners
  • Drug and device registration through the Drug Administration of Vietnam
  • Price controls on certain services and pharmaceuticals
  • Environmental and biosafety requirements for manufacturing facilities
  • Foreign ownership restrictions, which vary by sub-sector and are subject to ongoing revision

Conclusion

Vietnam's healthcare sector offers genuine, structural growth opportunities driven by demographics, income growth, and regulatory modernisation. But it is not a market for passive capital. Success requires deep understanding of local regulatory processes, relationships with provincial health authorities, and patience for the long development timelines that healthcare infrastructure demands.